23:51:26 EDT Thu 24 Jun 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Revive Therapeutics Ltd
Symbol RVV
Shares Issued 72,411,282
Close 2020-03-24 C$ 0.085
Recent Sedar Documents

Revive appoints Boulware as scientific adviser

2020-03-24 10:20 ET - News Release

Mr. Michael Frank reports

REVIVE THERAPEUTICS APPOINTS DR. DAVID BOULWARE, MD, AS SCIENTIFIC ADVISOR FOR INFECTIOUS DISEASES INCLUDING COVID-19

Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join Revive Therapeutics Ltd. as a scientific adviser to guide the company's current and future clinical programs, including its research and development strategy for infectious diseases, including COVID-19.

Dr. Boulware is an infectious disease physician-scientist and professor of medicine, division of infectious diseases and international medicine, at the University of Minnesota. Dr. Boulware is currently the principal investigator of a globally recognized COVID-19 clinical trial to determine if postexposure prophylaxis with hydroxychloroquine can prevent progression development of symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 virus. His primary research interests are in meningitis in resource-limited areas, including diagnosis, prevention, treatment and quality improvement initiatives, incorporating cost-effectiveness analyses in order to translate knowledge into improved care. Dr. Boulware's current research is focused on improving the clinical outcomes of HIV-infected (human immunodeficiency virus) persons with cryptococcal meningitis and tuberculosis meningitis. Dr. Boulware has active research collaborations in Uganda, Southern Africa and Ethiopia, where he leads a multidisciplinary, international research team. He serves on U.S. and World Health Organization panels for cryptococcal meningitis and World Health Organization panels for advanced HIV disease.

"We are pleased to have Dr. Boulware join us to assist in advancing the research and clinical development of our infectious disease initiatives, including exploring the use of bucillamine as a potential novel treatment for COVID-19," said Michael Frank, chief executive officer of Revive. "Dr. Boulware brings comprehensive clinical expertise in infectious diseases, and he will be valuable in guiding our clinical development strategy and product pipeline in infectious diseases."

"I am excited to assist Revive in their objective in pursuing the clinical development of bucillamine for infectious diseases and its prospect as a potential solution for COVID-19," said Dr. Boulware.

As previously announced, the company is exploring the use of bucillamine as a potential novel treatment for infectious diseases, including COVID-19. The company has applied for a provisional patent with the U.S. Patent and Trademark Office entitled, "Use of Bucillamine in the Treatment of Infectious Diseases." Revive plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the use of bucillamine in the treatment of COVID-19. Parts of the IND will be supported and referenced by the company's previous INDs accepted by the FDA and its phase 2 grant for the clinical investigation of bucillamine in the treatment of acute gout flares and cystinuria.

About Revive Therapeutics Ltd.

Revive Therapeutics is a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products. Revive's cannabinoid technology is being advanced to fill the medical needs for diseases and disorders, such as pain, inflammation and wound care. With its recent acquisition of Psilocin Pharma Corp., Revive will advance psilocybin-based therapeutics in various diseases and disorders, and will prioritize development efforts to take advantage of a number of regulatory incentives awarded by the Food and Drug Administration, such as orphan drug, fast-track, breakthrough therapy and rare pediatric disease designations.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.